MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience

    D. Fischer, R. Caskey, M. Dean, V. Sung (Birmingham, AL, USA)

    Objective: To evaluate real-world use and outcomes with deutetrabenazine for Huntington’s disease. Background: Grade A evidence for Huntington’s disease chorea treatment includes tetrabenazine and deutetrabenazine.…
  • MDS Virtual Congress 2020

    How Well Does the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) Reflect Disease Progression in Huntington’s disease (HD)?

    C. Snell, H. Smith, J. Castleton, A. Hall, A. Smirnova, B. Wright, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

    Objective: To examine the usefulness of the cUHDRS in reflecting disease progression in a well-characterized group of mild to moderate HD subjects followed at one…
  • MDS Virtual Congress 2020

    Striatal neurodegeneration in the presymptomatic phase of X-linked Dystonia-Parkinsonism

    H. Hanssen, M. Heldmann, J. Dy, J. Tantianpact, J. Steinhardt, A. Sprenger, A. Domingo, C. Reyes, R. Rosales, C. Klein, T. Münte, A. Westenberger, J. Oropilla, C. Diesta, N. Brüggemann (Luebeck, Germany)

    Objective: To identify structural brain changes in patients with X-linked dystonia-parkinsonism (XDP) and non-manifesting carriers of the TAF1 SVA retrotransposon insertion (NMC). Background: XDP is…
  • MDS Virtual Congress 2020

    4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates

    T. Di Paolo, M. Bourque, R. Snodgrass (Quebec City, QC, Canada)

    Objective: This study investigated the antidyskinetic activity of 4-chlorokynurenine (AV-101) in parkinsonian monkeys with L-Dopa-induced dyskinesias. Background: The common treatment for Parkinson’s disease (PD) is L-Dopa…
  • MDS Virtual Congress 2020

    Frontal Cavernous angioma manifested as acquired dystonic tremor: Two case reports

    D. Chaity (Dublin, Ireland)

    Objective: To highlight unilateral slow dystonic tremor as an uncommon presentation of frontal cavernoma. Background: Acquired dystonia, results from injury to the brain, poisoning or…
  • MDS Virtual Congress 2020

    Long-term effect of non-invasive Vagus Nerve Stimulation in Parkinson’s disease patients

    H. Kumar, B. Mondal, S. Choudhury, R. Banerjee, A. Roy, K. Chatterjee, P. Basu, S. Baker, M. Baker (Kolkata, India)

    Objective: In this first ever, randomized, double-blind control trial we explored the role of noninvasive VNS (nVNS) in the treatment of gait and motor symptoms…
  • MDS Virtual Congress 2020

    Measurement of speech as a biomarker of neurodegenerative disease using acoustic profiles and machine learning

    B. Schultz, Z.. Joukhader, U. Nattala, G. Noffs, J. Chan, S. Rojas-Azaocar, H. Reece, M. Magee, M. Delatycki, L. Corben, A. Walt, A. Vogel (Melbourne, Australia)

    Objective: To examine the utility of speech biometrics for describing and delineating neurodegenerative diseases using acoustic measures and machine learning procedures. Background: Progressive neurological disorders…
  • MDS Virtual Congress 2020

    Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France

    M. Auffret, J. Keromnes, G. Robert, V. Morel, M. Vérin (Rennes, France)

    Objective: To assess the current practice regarding patients with Parkinson’s disease (PD) in palliative care units and to identify barriers to patients’ referral and optimal…
  • MDS Virtual Congress 2020

    A brain signature of prodromal Lewy body dementia

    S. Rahayel, R. Postuma, J. Montplaisir, B. Mišić, C. Tremblay, C. Yao, M. Gaubert, J. Carrier, O. Monchi, F. Blanc, S. Chouinard, M. Panisset, A. Dagher, J.F Gagnon (Montreal, QC, Canada)

    Objective: To investigate the presence of a brain signature able to predict the development of dementia in patients with idiopathic REM sleep behavior disorder (iRBD).…
  • MDS Virtual Congress 2020

    Cholinergic basal forebrain atrophy and cognitive decline in advanced Parkinson’s disease

    M. Cohn, V. Mutreja, M. Statucka, T. Schmitz (Toronto, ON, Canada)

    Objective: To examine the relationship between cognitive decline and atrophy across cholinergic basal forebrain (BF) subregions in advanced Parkinson’s disease (PD). Background: Recent studies show…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley